Fargesone A
- CAS No.
- 116424-69-2
- Chemical Name:
- Fargesone A
- Synonyms
- Fargesone A;(2S,3R,3aR,7S,7aS)-2-(1,3-benzodioxol-5-yl)-3a,4-dimethoxy-3-methyl-7-prop-2-enyl-2,3,7,7a-tetrahydro-1-benzofuran-6-one;6(2H)-Benzofuranone, 2-(1,3-benzodioxol-5-yl)-3,3a,7,7a-tetrahydro-3a,4-dimethoxy-3-methyl-7-(2-propen-1-yl)-, (2R,3S,3aS,7S,7aR)-;[2R-(2alpha,3beta,3abeta,7alpha,7abeta)]-2-(1,3-Benzodioxol-5-yl)-3,3a,7,7a-tetrahydro-3a,4-dimethoxy-3-methyl-7-(2-propenyl)-6(2H)-benzofuranone
- CBNumber:
- CB61470473
- Molecular Formula:
- C21H24O6
- Molecular Weight:
- 372.41
- MDL Number:
- MFCD26406196
- MOL File:
- 116424-69-2.mol
- MSDS File:
- SDS
| Product description | Number | Pack Size | Price |
| FargesoneA ≥98% | CFN96245 | 5mg | $463 |
| FargesoneA 95+% | CD32002782 | 5mg | $730 |
Fargesone A Chemical Properties,Uses,Production
Uses
Fargesone A is a potent and selective FXR agonist. Fargesone A shows anti-inflammatory activity[1].
Definition
ChEBI: Fargesone A is a member of benzodioxoles.
in vivo
Fargesone A (3 and 30 mg/kg; i.p.; daily for 7 days) significantly ameliorates pathological features in bile duct ligation (BDL)-induced chronic liver fibrosis mouse model[1].
Pharmacokinetics parameters of Fargesone A in mice
| t1/2 (h) | Tmax (h) | Cmax (ng/mL) | AUC0-t (ng/mL*h) | AUC0-inf (ng/mL*h) | MRT0-inf (h) | F (%) | |
| i.v. (5 mpk) | 0.68±0.1 | - | 941±57 | 469±13 | 471±14 | 0.43±0.13 | - |
| p.o. (10 mpk) | 0.33±0.04 | 0.25±0.00 | 104±16 | 101±32 | 102±32 | 0.58±0.07 | 10.8±3.2 |
| Animal Model: | C57BL/6 mice, bile duct ligation (BDL)-induced chronic liver fibrosis mouse model[1] |
| Dosage: | 3 and 30 mg/kg |
| Administration: | IP, once daily for 7 days |
| Result: | Resulted in a lower level of inflammatory infiltrates and a smaller amount of collagen deposition compared to the vehicle group. Reversed BDL-induced sharp increase in total bilirubin level in the serum. Significantly decreased liver mRNA expression of the inflammatory biomarkers interleukin (IL)-6, IL-1β, inducible nitric oxide synthase (iNOS), and prostaglandin-endoperoxide synthase 2 (COX2). |
| Animal Model: | C57BL6/J mice[1] |
| Dosage: | 5 or 10 mg/kg |
| Administration: | IV or PO (Pharmacokinetics Analysis) |
| Result: | Showed acceptable PK profiles in general. |
References
[1] Guo F, et al. Biomimetic Total Synthesis and the Biological Evaluation of Natural Product (-)-Fargesone A as a Novel FXR Agonist. JACS Au. 2022 Dec 7;2(12):2830-2838. DOI:10.1021/jacsau.2c00600
Fargesone A Preparation Products And Raw materials
Raw materials
Preparation Products
Fargesone A Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Career Henan Chemica Co | +86-0371-86658258 +8613203830695 | laboratory@coreychem.com | China | 30228 | 58 |
| Labnetwork lnc. | +86-27-50766799 +8618062016861 | contact@labnetwork.com | China | 19987 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; | support@targetmol.com | United States | 39042 | 58 |
| BioBioPha Co., Ltd. | 0871-65217109 13211707573; | y.liu@mail.biobiopha.com | China | 5645 | 65 |
| Wuxi Zhongkun Biochemical Technology Co., Ltd. | 0510-85629785 18013409632 | sales@reading-chemicals.com | China | 15178 | 58 |
| Shanghai Yongye Biotechnology Co., Ltd. | 86-021-61559134 15921386130 | 3423497944@qq.com | China | 8144 | 55 |
| Wuhan ChemFaces Biochemical Co., Ltd. | 18607101326 15172504745 | aileen@chemfaces.com | China | 6905 | 55 |
| EMMX Biotechnology LLC | 888-539-0666 | info@emmx.com | United States | 8447 | 60 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 021-61312847; 18021002903 | 3008007409@qq.com | China | 86249 | 60 |
| Shanghai ChengShao Biological Technology Co., Ltd. | 021-61847300 13341622919 | shcss01@163.com | China | 4808 | 58 |
